<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948908</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL7510</org_study_id>
    <nct_id>NCT01948908</nct_id>
  </id_info>
  <brief_title>Volumes of Administration for Intranasal Midazolam</brief_title>
  <official_title>Optimal Volumes of Administration for Intranasal Midazolam in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intranasal route is an effective means of administering sedative medications for
      children. However, sometimes the child has to receive a certain dose that requires a very
      large volume to be administered into the nose, because of the types of concentrations of
      drugs that are available. Most drugs are not concentrated enough so that small volumes can
      be consistently given, so as a result, sometimes a very large amount of medication is
      administered intranasally. When the amount is too large, most of the medication either runs
      back out the nose, or down the back of the nose and throat and is swallowed, instead of
      being absorbed in the nasal cavity, where it can be quickly absorbed and produce optimal
      effectiveness. The purpose of this study is to determine exactly how much volume should be
      administered into each nare, so that the absorption can be maximized and the amount that
      runs out of the nose, or is swallowed, is minimized, thereby optimizing the effectiveness of
      any drug given intranasally. The investigators will determine this ideal &quot;volume of
      administration&quot; by studying intranasal midazolam in children who require sedation to
      facilitate laceration repairs. The investigators will evaluate both clinical outcomes as
      well as pharmacokinetic outcomes associated with each volume of administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to onset of minimal sedation</measure>
    <time_frame>20 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time (minutes) after administration of intranasal midazolam until patient achieves minimal sedation, defined as a University of Michigan Sedation Score (UMSS) of 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of sedation</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Observational Scale of Behavioral Distress - Revised (OSBD-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of midazolam</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of Cmax (maximum concentration) and Tmax (time to maximum concentration) of midazolam after intranasal administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIS monitoring</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>BIS scores during procedural sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction of parents, proceduralist MD, and MD administering intranasal medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Children Requiring Sedation to Facilitate Laceration Repair.</condition>
  <arm_group>
    <arm_group_label>200 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 200 mcL VOA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 500 mcL VOA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mcL VOA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal midazolam administered in 1000 mcL VOA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal midazolam</intervention_name>
    <description>Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).</description>
    <arm_group_label>200 mcL VOA</arm_group_label>
    <arm_group_label>500 mcL VOA</arm_group_label>
    <arm_group_label>1000 mcL VOA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1 to 7 years of age, inclusive.

          -  Require intranasal midazolam for minimal sedation to facilitate laceration repair.

        Exclusion Criteria:

          -  Weight less than 10 kg.

          -  Known allergy to midazolam.

          -  Presence of intranasal obstruction (e.g. mucous or blood) that cannot be readily
             cleared

          -  Inability to speak English or Spanish

          -  Developmental delay, psychiatric illness, neurologic impairment, or altered mental
             status; or illnesses associated with chronic pain (e.g. sickle cell disease,
             inï¬‚ammatory bowel disease).

          -  Foster children or wards.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel S Tsze, MD, MPH</last_name>
    <phone>212-305-9825</phone>
    <email>dst2141@columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel S Tsze, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter S Dayan, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Serge Cremers, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>June 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Daniel Sing-Kwong Tsze</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Laceration repair</keyword>
  <keyword>Children</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Midazolam</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lacerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
